Dashboard
Manage Tickers

BIIB BIOGEN INC.

Nasdaq biogen.com


$ 150.26 $ 0.00 (0 %)    

Friday, 24-Oct-2025 08:13:09 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 616.55 $ 0.00 (0 %)
DIA $ 469.83 $ 0.00 (0 %)
SPY $ 676.48 $ 0.00 (0 %)
TLT $ 91.71 $ 0.00 (0 %)
GLD $ 375.99 $ 0.00 (0 %)
$ 150.08
$ 148.38
$ 149.98 x 13
$ 150.98 x 1
-- - --
$ 110.04 - $ 187.58
1,245,964
na
22B
$ 0.60
$ 14.38
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 04-24-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 07-25-2023 06-30-2023 10-Q
10 04-25-2023 03-31-2023 10-Q
11 02-15-2023 12-31-2022 10-K
12 10-25-2022 09-30-2022 10-Q
13 07-20-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-03-2022 12-31-2021 10-K
16 10-20-2021 09-30-2021 10-Q
17 07-22-2021 06-30-2021 10-Q
18 04-22-2021 03-31-2021 10-Q
19 02-03-2021 12-31-2020 10-K
20 10-21-2020 09-30-2020 10-Q
21 07-22-2020 06-30-2020 10-Q
22 04-23-2020 03-31-2020 10-Q
23 02-06-2020 12-31-2019 10-K
24 10-22-2019 09-30-2019 10-Q
25 07-24-2019 06-30-2019 10-Q
26 04-24-2019 03-31-2019 10-Q
27 02-06-2019 12-31-2018 10-K
28 10-23-2018 09-30-2018 10-Q
29 07-24-2018 06-30-2018 10-Q
30 04-24-2018 03-31-2018 10-Q
31 02-01-2018 12-31-2017 10-K
32 10-24-2017 09-30-2017 10-Q
33 07-25-2017 06-30-2017 10-Q
34 04-25-2017 03-31-2017 10-Q
35 02-02-2017 12-31-2016 10-K
36 10-26-2016 09-30-2016 10-Q
37 07-21-2016 06-30-2016 10-Q
38 04-21-2016 03-31-2016 10-Q
39 02-03-2016 12-31-2015 10-K
40 10-21-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

biogen-and-vanqua-bio-announce-agreement-granting-biogen-exclusive-worldwide-rights-to-vanquas-c5ar1-antagonist-vanqua-to-receive-70m-upfront-and-up-to-990m-in-miletones
Biogen And Vanqua Bio Announce Agreement G...
10/24/2025 11:32:46

biogen-to-present-data-from-trials-evaluating-dapirolizumab-pegol-at-american-college-of-rheumatology-convergence-2025-in-chicago
Biogen To Present Data From Trials Evaluat...
10/22/2025 11:37:56

Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc...

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

biogen-says-estimated-charge-expected-to-impact-gaap--non-gaap-net-income-per-diluted-share-for-q3-by-001-per-share-expects-q3-results-to-include-acquired-in-process-rd-upfront-and-milestone-expense-of-about-2m-on-pre-tax-basis
Biogen Says Estimated Charge Expected To I...
10/14/2025 20:23:09

- SEC Filing

7-analysts-have-this-to-say-about-biogen
7 Analysts Have This To Say About Biogen
10/10/2025 19:00:46

morgan-stanley-maintains-equal-weight-on-biogen-raises-price-target-to-149
Morgan Stanley Maintains Equal-Weight on B...
10/10/2025 17:36:30

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from ...

Core News & Articles
Biogen And Stoke Announce Phase 3 Zorevune...
10/09/2025 20:32:46

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

eisai-and-biogen-announce-lecanemab-irmb-subcutaneous-injection-is-now-available-in-us-as-maintenance-dosing-regimen-for-ad-treatment
Eisai And Biogen Announce Lecanemab-Irmb S...
10/06/2025 20:34:02

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nu...

nasdaq-100-top-25000-as-amd-spikes-gold-eyes-4000-whats-moving-markets-monday
Nasdaq 100 Top 25,000 As AMD Spikes, Gold ...
10/06/2025 17:02:18

Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ...

trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years
Trump-Pfizer Deal Pushes Health Care Stock...
10/01/2025 20:22:35

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday
Health Care Stocks Rally, Nike Beats The S...
10/01/2025 16:56:36

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

Core News & Articles
Reported Sunday, Eisai And Biogen Secure C...
09/29/2025 06:32:45

trumps-100-pharmaceutical-tariff-the-270-billion-manufacturing-war-that-could-reshape-your-medicine-cabinet
Trump's 100% Pharmaceutical Tariff: The $2...
09/26/2025 12:01:51

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creatin...

biogen-faces-fda-setback-on-high-dose-nusinersen-filing-for-spinal-muscular-atrophy
Biogen Faces FDA Setback On High-Dose Nusi...
09/25/2025 15:27:51

On Tuesday, the U.S.

this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Lululemon Analyst Is No Longer Bullis...
09/25/2025 12:56:47

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Biogen Analyst Begins Coverage On A B...
09/25/2025 12:42:57

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

jefferies-initiates-coverage-on-biogen-with-buy-rating-announces-price-target-of-190
Jefferies Initiates Coverage On Biogen wit...
09/25/2025 11:05:38

Jefferies analyst Andrew Tsai initiates coverage on Biogen (NASDAQ: BIIB) with a Buy rating and announces Price Target of $1...

what-6-analyst-ratings-have-to-say-about-biogen
What 6 Analyst Ratings Have To Say About B...
09/24/2025 12:00:34

eisai-and-biogens-leqembi-approved-by-australias-tga-for-early-alzheimers-in-apoe4-non-carriers-and-heterozygotes
Eisai And Biogen's LEQEMBI Approved By Aus...
09/24/2025 11:34:09

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...

needham-reiterates-hold-on-biogento-hold
Needham Reiterates Hold on Biogento Hold
09/24/2025 10:11:32

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) from Hold to Hold.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION